Erik B Oleson
Overview
Explore the profile of Erik B Oleson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behler A, George N, Collibee C, Hamilton L, Oleson E, Thamotharan S
Cult Health Sex
. 2022 Jul;
25(6):791-802.
PMID: 35900895
Queer, Black womxn experience sexual assault at an alarming rate in the USA leading to adverse mental and physical health outcomes in survivors. A synthesis of the literature was conducted...
2.
Oleson E, Hamilton L, Gomez D
Front Synaptic Neurosci
. 2021 Jun;
13:660218.
PMID: 34177546
Motivational and attentional processes energize action sequences to facilitate evolutionary competition and promote behavioral fitness. Decades of neuropharmacology, electrophysiology and electrochemistry research indicate that the mesocorticolimbic DA pathway modulates both...
3.
Oleson E, Khokhar J
Prog Neuropsychopharmacol Biol Psychiatry
. 2021 Mar;
110:110305.
PMID: 33737216
Cannabinoids from the cannabis plant were one of the earliest psychoactive phytochemicals harnessed by humanity for their medicinal properties and remain one of the most frequently used and misused classes...
4.
Gomez D, Everett T, Hamilton L, Ranganath A, Cheer J, Oleson E
Neuropharmacology
. 2020 Oct;
182:108374.
PMID: 33115642
Synthetic cannabinoids were introduced into recreational drug culture in 2008 and quickly became one of the most commonly abused drugs in the United States. The neurobiological consequences resulting from synthetic...
5.
Isaacs D, Leman R, Everett T, Lopez-Beltran H, Hamilton L, Oleson E
Neuropsychopharmacol Rep
. 2020 Sep;
40(4):355-364.
PMID: 32935483
Aims: The United States of America is currently in an opioid epidemic. Heroin remains the most lethal opioid option with its death rate increasing by over 500% in the last...
6.
Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance
Everett T, Gomez D, Hamilton L, Oleson E
Prog Neuropsychopharmacol Biol Psychiatry
. 2020 Jul;
104:110031.
PMID: 32663486
Endocannabinoids (eCBs) are neuromodulators that influence a wide range of neural systems and behaviors. In the current review, we describe our recent research showing how eCBs, particularly 2-arachidonoylglycerol (2-AG), concurrently...
7.
Peters K, Oleson E, Cheer J
Cold Spring Harb Perspect Med
. 2020 Jan;
11(1).
PMID: 31964646
like all known drugs of abuse, leads to increased dopamine activation within the mesolimbic pathway. Consequent dopamine release within terminal regions of the striatum is a powerful mediator of reward...
8.
Oleson E, Roberts J
Brain Res
. 2018 Dec;
1713:32-41.
PMID: 30543771
The mesocorticolimbic dopamine pathway is generally considered to be a reward pathway. While shortsighted, there is a strong basis for this view of dopamine function. Here, we first describe the...
9.
Hake H, Davis J, Wood R, Tanner M, Loetz E, Sanchez A, et al.
Physiol Behav
. 2018 Dec;
199:343-350.
PMID: 30529341
Clinical trials have demonstrated that 3,4-methylenedioxymethamphetamine (MDMA) paired with psychotherapy is more effective at reducing symptoms of post-traumatic stress disorder (PTSD) than psychotherapy or pharmacotherapy, alone or in combination. The...
10.
Brodnik Z, Batra A, Oleson E, Espana R
ACS Chem Neurosci
. 2018 Sep;
10(4):1978-1985.
PMID: 30253088
Benzodiazepines make up a class of psychoactive drugs that act as allosteric co-activators of the inhibitory GABA receptor. These drugs are useful for the treatment of several psychiatric disorders but...